Skip to content
Open access

Integrated hs-cTnI, global longitudinal strain, and coronary artery calcium for risk stratification of anthracycline-related cardiac dysfunction in multiple myeloma

Oct 2026 · Frontiers in Cardiovascular Medicine · Vol 13 · 0 citations · 50 references
Medicine

Abstract

Background Anthracycline-related cardiac dysfunction remains a major concern in multiple myeloma, yet conventional left ventricular ejection fraction (LVEF) surveillance may miss early injury. We evaluated whether pre-anthracycline baseline measurements of high-sensitivity cardiac troponin I (hs-cTnI), global longitudinal strain (GLS), and coronary artery calcium (CAC), obtained before anthracycline initiation, improve risk stratification for cancer therapy-related cardiac dysfunction (CTRCD). Methods In this retrospective study of 312 myeloma patients receiving anthracycline-based therapy, CTRCD was defined as LVEF decline >10% to <53% or relative GLS decline >15%. Predictive performance was assessed using competing-risk models and time-dependent ROC analysis. A simplified risk score (MY-CARD) was derived and temporally validated in a separate cohort. Results CTRCD occurred in 91 patients (29.2%). hs-cTnI elevation and GLS worsening preceded LVEF decline, with median intervals of 8.4 and 12.6 weeks. The full model (hs-cTnI + GLS + CAC) achieved an AUC of 0.91, outperforming hs-cTnI + LVEF (0.83) and LVEF alone (0.66). The MY-CARD score stratified 12-month CTRCD risk into low (6.2%), intermediate (28.7%), and high (71.4%) categories. Patients with both hs-cTnI elevation and GLS worsening had the highest subsequent CTRCD risk (adjusted HR 5.42–7.86). Conclusions Integrating baseline hs-cTnI, GLS, and CAC improved CTRCD risk stratification in myeloma patients. The MY-CARD score provides a practical framework for baseline and on-treatment risk assessment, supporting closer surveillance in high-risk patients. External validation and prospective studies are warranted.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.